Synthesis of HNMT, NNMT intermediates and PK 75N95025Q00236
Summary
AI-generated · Aug 27, 2025Provide custom synthesis and bioanalytical support for two NCATS projects focused on inhibitors of physiological small molecule methyltransferases implicated in disease. Deliver key intermediates to enable scale-up of lead compounds and creation of analogs, and generate tissue-exposure data to gauge concentrations in tissues of interest to help select compounds for proof of concept (POC).
Deliverables include 100 grams of N-(pyridin-3-yl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-e][1,4]diazepin-8-amine and 100 grams of tert-butyl (R)-3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)piperidine-1-carboxylate. Perform mouse pharmacokinetics on at least 10 compounds with routes and tissues determined. Final products must be >95% pure with optical purity >98%, and spectroscopic characterization and analytical data must be provided and verified.
NCATS is in need of custom synthesis and bioanalytical services in internal projects focused on developing small molecule inhibitors of physiological small molecule methyltransferases. NACTS is pursuing small molecules in two projects where methyltransferases are implicated in disease. NCATS requires key intermediates that will allow for the lab to scale up lead compounds or make analogs. NCATS also requires exposure data in various tissues of interest to gauge compound concentrations to select compounds for POC. 100g of N-(pyridin-3-yl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-e][1,4]diazepin-8-amine 100g of (tert-butyl (R)-3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3- yl)piperidine-1- carboxylate. Mouse PK on at least 10 compounds with routes and tissues determined. The final purity has to be >95% with optical purity >98%. Spectroscopic characterization and analytical data will be required and verified.
From Presolicitation posted on Aug 12, 2025Notice history
1Details
Award Information
Not yet awarded
Contacts
Phone
Phone
Agency
Place of Performance
USA